Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on INT 1. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113717178A discloses a scalable method for chiral 7-azabicyclo[2.2.1]heptane intermediates, offering improved purity and cost efficiency for oncology drug manufacturing.
Patent CN112939892A reveals a green Ru-catalyzed route for quetiapine intermediates. Achieve high purity and yield with water as the only byproduct for cost-effective API manufacturing.
Novel CS2-free route for Epalrestat intermediate. Enhanced safety, solid intermediates, scalable manufacturing for global supply chains.
Novel selective synthesis method for diltiazem intermediate improves yield and purity. Cost-effective supply chain solution for pharmaceutical manufacturing partners globally.
Patent CN101100459B details a low-cost, high-yield method for Rosuvastatin aldehyde intermediates, offering significant supply chain advantages.
Patent CN115894525A reveals a novel cyclization method yielding >99.9% purity intermediates, offering significant cost and supply chain advantages for global pharma manufacturers.
Novel CN116239593B process for Vericiguat intermediate. High yield, short route, cost-effective manufacturing for global supply chains and procurement.
Patent CN101747273B reveals a novel two-step synthesis for Blonanserin intermediates, boosting yield from 17% to 80% and ensuring reliable pharmaceutical intermediates supply.
Patent CN109293513B reveals a novel metal-mediated route for Sitafloxacin Intermediate II, offering >96% yield and simplified purification for reliable API manufacturing.
Patent CN108409557A reveals high-purity Brivaracetam intermediate synthesis. This technology offers significant cost reduction and enhanced supply chain reliability for global pharmaceutical manufacturing partners.
Patent CN117299207A reveals novel supported catalyst for GalNAc intermediate synthesis offering higher yield and safer scalable production for pharmaceutical supply chains.
Novel patent CN108658956A offers scalable eribulin intermediate synthesis. Reduces steps, enhances purity for reliable pharmaceutical intermediate supply chains.
Patent CN102093278B reveals a novel synthesis for Doripenem Intermediate I, achieving 99.5% purity and >75% yield via eco-friendly reagents and optimized coupling.
Patent CN108033906A reveals high-yield Silodosin intermediate synthesis. Discover cost reduction and supply chain advantages for pharmaceutical manufacturing.
Patent CN102199162A details a green synthesis for olanzapine intermediates, reducing toxic tin usage and ensuring high purity for cost-effective API manufacturing.
Patent CN104447451A reveals safer Oseltamivir intermediate synthesis avoiding sodium azide. Enhances supply chain reliability and reduces manufacturing costs significantly.
Patent CN109797174B reveals high-yield ketoreductase route. Reduces heavy metal waste, ensures 100% ee. Ideal for veterinary API supply chains.
Patent CN102219780B enables stable yield Rosuvastatin intermediate manufacturing. Reduces complexity for pharmaceutical intermediates supply chain.
Patent CN111320535B reveals a low-cost route for 3-(benzyloxy)-1-cyclobutanone using Hunsdiecker reaction, offering significant supply chain advantages for API manufacturing.
Patent CN120097997A reveals catalytic oxidation for high-purity camptothecin intermediates. Enables cost reduction and scalable pharmaceutical intermediates manufacturing.